Industry Insights

• 
  Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China Kevin
  April 28, 2025
  This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.
• 
  Taking Over the "King of Medicine"? Chinese Enterprises Lead the Development of PD-(L)1/VEGF Bispecific Antibody Antitumor Drug Kevin
  April 28, 2025
  PD-(L)1 and VEGF (vascular endothelial growth factor) bispecific antibody therapies are considered a key direction for future tumor treatments, attracting increasing global interest due to their unique mechanism of action and promising clinical data.
• 
  Another BlockBuster in HKEX18A Biotech Companies: IPO of DualityBio in Hong Kong, Introducing New Capital Engine in the ADC Field? Kevin
  April 15, 2025
  On April 15, DualityBio, a rising star in the ADC field, was officially listed on the HKEX, marking one of the most high-profile IPOs in recent years in Chapter 18A Biotech Companies.

• 
  3D Printing in Pharmaceuticals: Transforming Drug Design, Production, and Delivery Saher Haider
  May 06, 2025
  This article will explore 3D printing's current applications in pharmaceutical production, personalized medicine, and drug discovery, and the future potential of this groundbreaking technology.

• 
  Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China ACN Newswire
  May 07, 2025
• 
  InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA PharmaSources
  May 06, 2025
• 
  HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress ACN Newswire
  April 25, 2025
  HighTide Therapeutics announced that it will present at the EASL Congress 2025. The presentations include New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010).

• 
  Popular Products and Companies at PharmaSources.com (January 2025) PSI
  January 15, 2025
  Popular Products and Companies at PharmaSources.com
• 
  Research and Application of Artemisia Argyi Xiaonisha
  August 12, 2024
• 
  Research Progress on the Application of Biologics in Pediatric Asthma Xiaomichong
  July 19, 2024

• 
  20 Years of Growth and Innovation in China, Fette Compacting Launches F30p Tablet Press PharmaSources
  December 13, 2024
  Interview Dr. Andreas Risch——Managing Director of Fette Compacting (China) Co., Ltd.